Targets & Tactics: A Bispecific Master Class for the AP

Modules:

Module 1: Clinical Application of Bispecific T-Cell Engagers

Module 2: Bispecific T-Cell Engager Related Adverse Events

Module 3: Implementing Bispecific T-Cell Engagers Into Practice: Mode

  • Module 1: Clinical Application of BTCE's
    Contains 8 Component(s), Includes Credits
    Component Credit Type State/Medical Type Available Credits Earned Credits
    CE Certificates: Clinical Application of BTCE's Medical PA 1.00 0.00
    CE Certificates: Clinical Application of BTCE's Medical PharmD 1.00 0.00
    CE Certificates: Clinical Application of BTCE's Medical NP/Nursing 1.00 0.00
    CE Certificates: Clinical Application of BTCE's Medical Attendance (Other) 1.00 0.00

    Advanced practitioners will gain practical knowledge of the therapeutic roles of BTCEs in multiple myeloma, lymphoma, and small cell lung cancer. The course emphasizes how to evaluate evidence from landmark trials, apply guideline-based recommendations, and tailor therapy using real-world clinical scenarios. By the end of the session, learners will be able to compare BTCEs to other treatment modalities and optimize care through patient-specific decision-making.

    • Introduction
    • Taking a "Bite: out of Multiple Myeloma
    • Taking a "Bite" Out of Lymphoma
    • Taking a "Bite" Out of Small Cell Lung Cancer


      After completing this activity, the participant should be better able to:

      •       Discuss mechanisms of action and therapeutic roles of US Food and Drug Administration (FDA)-approved bispecific T-cell engagers (BTCEs) in hematology/oncology malignancies.

      •       Evaluate clinical trial data and guideline recommendations for BTCEs in multiple myeloma, lymphoma, and small cell lung cancer.

      •       Apply patient-specific factors to individualize treatment plans for patients receiving BTCE therapy.

      •       Compare BTCEs to other immunotherapeutic approaches, such as chimeric antigen receptor T-cell therapy, in terms of efficacy, safety, and logistics.

      C. Brooke Adams, PharmD, BCOP

      Orlando Health Cancer Institute

      C. Brooke Adams is a board-certified Clinical Pharmacy Specialist in Malignant Hematology, Stem Cell Transplantation, and Cellular Therapy and the PGY-2 Oncology Residency Program Coordinator at the Orlando Health Cancer Institute. She completed her Doctorate of Pharmacy with research concentration at East Tennessee State University and her PGY-1 pharmacy practice and PGY-2 oncology residencies at Indiana University Health. She is a preceptor for UF and LECOM pharmacy students, PGY-1 and PGY-2 residents and is extensively involved in the education of hematology/oncology fellows and advanced practice providers. She is an active member of HOPA, FLASCO, NCODA, the OPN-FL Chapter, and ASTCT. She recently received the New Practitioner Award from HOPA in 2023 and is a member of the 2022 class of 40 under 40 in cancer presented by AVBCC.

      C. Brooke Adams, PharmD, BCOP, has the following financial relationships to disclose, Pfizer, Genmab/AbbVie, Incyte, BMS, Advisory board: Genmab/AbbVie, Amgen, GSK, Johnson & Johnson, Consultant: BMS, Johnson & Johnson.

      Emilie Aschenbrenner, PharmD, BCOP

      Medical College of Wisconsin

      Emilie Aschenbrenner is a board-certified Clinical Pharmacist in Stem Cell Transplantation and Cellular Therapy and the Hematology Clinical Coordinator at Froedtert and the Medical College of Wisconsin. She completed her Doctorate of Pharmacy at the University of Wisconsin, Madison and her PGY-1 pharmacy practice residency at Froedtert Hospital. She is a preceptor for PGY-1 and PGY-2 residents. She is an active member of HOPA, NCODA, Pharmacy Society of Wisconsin, and ASTCT and recently served on the CTN Pharmacy Research Committee. In addition, she has authored review articles, presented research posters, and given presentations both regionally and nationally.

      Emilie Aschenbrenner, PharmD, BCOP, has the following financial relationships to disclose, BMS, Astellas, Incyte, Genmab/AbbVie, Sanofi, BeiOne, Amgen, Advisory board: Amgen, Regeneron, Syndax

      Megan May, PharmD, BCOP, FHOPA, FAPO

      Baptist Health Lexington’s Cancer Center

      Megan May is a Clinical Oncology Pharmacy Specialist at Baptist Health Lexington’s Cancer Center in Lexington, Kentucky. She received her Doctor of Pharmacy from Samford University’s McWhorter School of Pharmacy in Birmingham, Alabama, and completed a Pharmacy Practice Residency at Shands Jacksonville Medical Center and a Hematology/Oncology Pharmacy Residency at the Medical University of South Carolina. She is a Board-Certified Oncology Pharmacist. In addition to direct patient care, Dr. May plays an active role in the education of pharmacy students and residents. She has been involved at the national level with a number of professional organizations on various committees and positions over the years. In addition, she has authored review articles, presented research posters, and given presentations both regionally and nationally.

      Megan May, PharmD, BCOP, FHOPA, FAPO, has the following financial relationships to disclose, Amgen, AstraZeneca, Advisory board: Amgen, Consultant: Amgen

    • Module 2: BTCE Related Adverse Events
      Contains 8 Component(s), Includes Credits
      Component Credit Type State/Medical Type Available Credits Earned Credits
      CE Certificates: BTCE Related Adverse Effects Medical PA 1.00 0.00
      CE Certificates: BTCE Related Adverse Effects Medical PharmD 1.00 0.00
      CE Certificates: BTCE Related Adverse Effects Medical NP/Nursing 1.00 0.00
      CE Certificates: BTCE Related Adverse Effects Medical Attendance (Other) 1.00 0.00

      Participants will gain practical expertise in recognizing the diverse toxicity profiles of BTCEs and implementing best practices for prophylaxis and intervention. Emphasis is placed on patient, caregiver, and provider education, as well as institution-specific protocols for rapid response. By completing this module, advanced practitioners will be prepared to mitigate toxicities, employ evidence-based supportive care measures, and ensure safe continuation of therapy.

      • Introduction
      • Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome
      • Infectious Complications of BTCEs
      • Unique Adverse Events
      • Summary

      After completing this activity, the participant should be better able to:

      •       Review the adverse event profiles of current bispecific T-cell engagers (BTCEs).

      •       Develop best practices to mitigate adverse events associated with BTCEs.

      •       Identify unique toxicities and infectious complications associated with BTCEs and their appropriate prophylactic measures.

      •       Emphasize the importance of patient and caregiver education for early recognition and management of toxicities.

      Megan May, PharmD, BCOP, FHOPA, FAPO

      Baptist Health Lexington’s Cancer Center

      Megan May is a Clinical Oncology Pharmacy Specialist at Baptist Health Lexington’s Cancer Center in Lexington, Kentucky. She received her Doctor of Pharmacy from Samford University’s McWhorter School of Pharmacy in Birmingham, Alabama, and completed a Pharmacy Practice Residency at Shands Jacksonville Medical Center and a Hematology/Oncology Pharmacy Residency at the Medical University of South Carolina. She is a Board-Certified Oncology Pharmacist. In addition to direct patient care, Dr. May plays an active role in the education of pharmacy students and residents. She has been involved at the national level with a number of professional organizations on various committees and positions over the years. In addition, she has authored review articles, presented research posters, and given presentations both regionally and nationally.

      Megan May, PharmD, BCOP, FHOPA, FAPO, has the following financial relationships to disclose, Amgen, AstraZeneca, Advisory board: Amgen, Consultant: Amgen

      Emilie Aschenbrenner, PharmD, BCOP

      Medical College of Wisconsin

      Emilie Aschenbrenner is a board-certified Clinical Pharmacist in Stem Cell Transplantation and Cellular Therapy and the Hematology Clinical Coordinator at Froedtert and the Medical College of Wisconsin. She completed her Doctorate of Pharmacy at the University of Wisconsin, Madison and her PGY-1 pharmacy practice residency at Froedtert Hospital. She is a preceptor for PGY-1 and PGY-2 residents. She is an active member of HOPA, NCODA, Pharmacy Society of Wisconsin, and ASTCT and recently served on the CTN Pharmacy Research Committee. In addition, she has authored review articles, presented research posters, and given presentations both regionally and nationally.

      Emilie Aschenbrenner, PharmD, BCOP, has the following financial relationships to disclose, BMS, Astellas, Incyte, Genmab/AbbVie, Sanofi, BeiOne, Amgen, Advisory board: Amgen, Regeneron, Syndax

      C. Brooke Adams, PharmD, BCOP

      Orlando Health Cancer Institute

      C. Brooke Adams is a board-certified Clinical Pharmacy Specialist in Malignant Hematology, Stem Cell Transplantation, and Cellular Therapy and the PGY-2 Oncology Residency Program Coordinator at the Orlando Health Cancer Institute. She completed her Doctorate of Pharmacy with research concentration at East Tennessee State University and her PGY-1 pharmacy practice and PGY-2 oncology residencies at Indiana University Health. She is a preceptor for UF and LECOM pharmacy students, PGY-1 and PGY-2 residents and is extensively involved in the education of hematology/oncology fellows and advanced practice providers. She is an active member of HOPA, FLASCO, NCODA, the OPN-FL Chapter, and ASTCT. She recently received the New Practitioner Award from HOPA in 2023 and is a member of the 2022 class of 40 under 40 in cancer presented by AVBCC.

      C. Brooke Adams, PharmD, BCOP, has the following financial relationships to disclose, Pfizer, Genmab/AbbVie, Incyte, BMS, Advisory board: Genmab/AbbVie, Amgen, GSK, Johnson & Johnson, Consultant: BMS, Johnson & Johnson.

    • Module 3: Implementing Bispecific T-Cell Engagers Into Practice: Moderated Panel Discussion
      Contains 6 Component(s), Includes Credits
      Component Credit Type State/Medical Type Available Credits Earned Credits
      CE Certificates: Panel Discussion Medical PA 1.00 0.00
      CE Certificates: Panel Discussion Medical PharmD 1.00 0.00
      CE Certificates: Panel Discussion Medical NP/Nursing 1.00 0.00
      CE Certificates: Panel Discussion Medical Attendance (Other) 1.00 0.00

      Designed as an interactive exchange, this session highlights the pivotal role of advanced practitioners in ensuring safe and effective BTCE use. Panelists provide perspectives from hospital-based, academic, and community clinics to illustrate variations in workflow, care coordination, and institutional readiness. Learners will explore strategies to streamline multidisciplinary collaboration, enhance patient and caregiver education, and overcome logistical barriers in the adoption of BTCE therapy.

      • Introduction to BTCEs
      • The Patient Journey
      • Practice Settings
      • Multidisciplinary Education
      • CRS and ICANS Monitoring
      • Leveraging the EMR
      • Formulary Decisions
      • REMS Certification
      • Summary

      After completing this activity, the participant should be better able to:

      •       Identify solutions to streamline care coordination for patients receiving bispecific T-cell engager (BTCE) therapy across diverse practice settings.

      •       Employ multidisciplinary strategies to enhance the safe integration of BTCEs in clinical workflows.

      •       Emphasize the importance of patient and caregiver education for early recognition and management of toxicities.

      •       Examine institutional approaches to formulary decisions, education initiatives, and cost considerations for BTCEs.

      •       Outline the role of advanced practitioners in supporting BTCE implementation and long-term patient monitoring.

      Megan May, PharmD, BCOP, FHOPA, FAPO

      Baptist Health Lexington’s Cancer Center

      Megan May is a Clinical Oncology Pharmacy Specialist at Baptist Health Lexington’s Cancer Center in Lexington, Kentucky. She received her Doctor of Pharmacy from Samford University’s McWhorter School of Pharmacy in Birmingham, Alabama, and completed a Pharmacy Practice Residency at Shands Jacksonville Medical Center and a Hematology/Oncology Pharmacy Residency at the Medical University of South Carolina. She is a Board-Certified Oncology Pharmacist. In addition to direct patient care, Dr. May plays an active role in the education of pharmacy students and residents. She has been involved at the national level with a number of professional organizations on various committees and positions over the years. In addition, she has authored review articles, presented research posters, and given presentations both regionally and nationally.

      Megan May, PharmD, BCOP, FHOPA, FAPO, has the following financial relationships to disclose, Amgen, AstraZeneca, Advisory board: Amgen, Consultant: Amgen

      C. Brooke Adams, PharmD, BCOP

      Orlando Health Cancer Institute

      C. Brooke Adams is a board-certified Clinical Pharmacy Specialist in Malignant Hematology, Stem Cell Transplantation, and Cellular Therapy and the PGY-2 Oncology Residency Program Coordinator at the Orlando Health Cancer Institute. She completed her Doctorate of Pharmacy with research concentration at East Tennessee State University and her PGY-1 pharmacy practice and PGY-2 oncology residencies at Indiana University Health. She is a preceptor for UF and LECOM pharmacy students, PGY-1 and PGY-2 residents and is extensively involved in the education of hematology/oncology fellows and advanced practice providers. She is an active member of HOPA, FLASCO, NCODA, the OPN-FL Chapter, and ASTCT. She recently received the New Practitioner Award from HOPA in 2023 and is a member of the 2022 class of 40 under 40 in cancer presented by AVBCC.

      C. Brooke Adams, PharmD, BCOP, has the following financial relationships to disclose, Pfizer, Genmab/AbbVie, Incyte, BMS, Advisory board: Genmab/AbbVie, Amgen, GSK, Johnson & Johnson, Consultant: BMS, Johnson & Johnson.

      Emilie Aschenbrenner, PharmD, BCOP

      Medical College of Wisconsin

      Emilie Aschenbrenner is a board-certified Clinical Pharmacist in Stem Cell Transplantation and Cellular Therapy and the Hematology Clinical Coordinator at Froedtert and the Medical College of Wisconsin. She completed her Doctorate of Pharmacy at the University of Wisconsin, Madison and her PGY-1 pharmacy practice residency at Froedtert Hospital. She is a preceptor for PGY-1 and PGY-2 residents. She is an active member of HOPA, NCODA, Pharmacy Society of Wisconsin, and ASTCT and recently served on the CTN Pharmacy Research Committee. In addition, she has authored review articles, presented research posters, and given presentations both regionally and nationally.

      Emilie Aschenbrenner, PharmD, BCOP, has the following financial relationships to disclose, BMS, Astellas, Incyte, Genmab/AbbVie, Sanofi, BeiOne, Amgen, Advisory board: Amgen, Regeneron, Syndax

      Katie Marcucci, DMSc, PA-C, CPAAPA

      Tennessee Oncology

      Katie Marcucci is a PA-C at Tennessee Oncology in Nashville, TN, specializing in malignant hematology. With 14 years of experience across multiple specialties, she currently cares for patients with blood cancers using both traditional and novel therapies. Passionate about education, Katie is an AAPA-certified preceptor and adjunct professor at several PA programs in her home state of Tennessee. She earned her Master’s in PA Studies from the University of New England in 2011 and a Doctor of Medical Science in clinician education from A.T. Still University in 2024. Katie’s commitment to patient care and teaching defines her impactful career.

      Katie Marcucci has no relevant financial relationships to disclose.

    © APSHO 2025. All Rights Reserved. The content, materials, and intellectual property presented on this course, including but not limited to text, graphics, images, designs, logos, videos, and code, are the exclusive property of APSHO, unless otherwise noted. Unauthorized reproduction, distribution, or use of any content without prior written permission is strictly prohibited. For inquiries about licensing or permissions, please contact APSHO directly at info@apsho.org.